Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02463994 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
A Early Phase 1 study of Non-Small Cell Lung Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT02463994: Completed Early Phase 1 study of Non-Small Cell Lung Cancer, sponsored by University of Michigan Rogel Cancer Center.
NCT02463994 is a Early Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 12 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02463994, a Early Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on lung cancers and is known to block the effects of the body's immune system in attacking the cancer. Blocking this PD-L1 has been shown to improve the body's immune cells to attack and kill the cancer cells in non-small cell lung cancer. The goal of this study is to see if prior treatment with radiation will allow improved recognition of the cancer by the body's immune cells in the presence of MPDL3280A.
Primary Outcome
The primary outcome is overall response rate (ORR) to combination of HIGRT and MPDL3280A. The number of participants that respond to treatment will be determined. Response will be assessed by Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1, using primarily CT scans, immune response criteria and/or clinical benefit as assessed by the investigator.
Conditions Studied
Interventions
- DRUG MPDL3280A
- RADIATION Hypofractionated Radiotherapy
Study Locations (2)
Michigan
- The University of Michigan Comprehensive Cancer Center - Ann Arbor
Washington
- University of Washington, Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-11-07 |
| Phase | Early Phase 1 |
What the finished NCT02463994 record still lists
NCT02463994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which MPDL3280A is the first listed.
NCT02463994 reports a single indexed study location in Michigan, Washington.
Frequently Asked Questions
What is clinical trial NCT02463994 about?
NCT02463994 is a clinical study titled "A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC". The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on lung cancers and is know...
What is the current status of trial NCT02463994?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2015-10. Estimated completion is 2018-11-07.
What conditions does trial NCT02463994 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02463994?
The interventions under investigation include: MPDL3280A (DRUG), Hypofractionated Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02463994?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02463994 being conducted?
This trial has 2 study locations across Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02463994's enrollment target sits among peer trials
12 437th of 454 higher than 12 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
RECRUITING · Early Phase 1
-
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
RECRUITING · Early Phase 1
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
- NCT03312556 · 12 participants · NA
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia